Capricor Therapeutics, Inc.
corporate_fare Company Profile
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 39 items for CAPR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-21, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 12 rated 8 or above. Recent SEC coverage for CAPR spans 10-Q, 8-K.
Recent high-impact activity:
- Capricor Weighs Cost Cuts After Second FDA Rejection of Deramiocel
- FDA Rejects Capricor's Duchenne Cell Therapy, Deramiocel
- Deramiocel Meets Phase 3 HOPE-3 Primary Endpoint, But Cardiac Data Miss
- Capricor Q3 Loss Widens to $42.7M; Cash Falls to $198.5M Ahead of Nov 22 PDUFA
- Capricor Posts Wider Q3 Loss of 73 Cents, Zero Revenue vs $41.7M Expected
Financial Snapshot
Short Interest & Short Volume
7.38 days to coverFINRA reported short interest of 18,765,089 shares in CAPR as of the October 30, 2026 settlement, a 5.5% decrease from the prior period — about 7.4 days to cover at its recent average daily volume. On November 20, 2026, 65.0% of CAPR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.